About: Shunji Takahashi

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Shunji Takahashi Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher (ORCID 0000-0002-5031-1953)

Attributes	Values
rdf:type	Item
description	연구원 (ko) 研究者 (ja) wetenschapper (nl) дослідник (uk) 研究者 (zh) researcher (ORCID 0000-0002-5031-1953) (en)
rdfs:label	Shunji Takahashi (en) Shunji Takahashi (nl) Shunji Takahashi (tr) Shunji Takahashi (ast) 高橋俊二 (ja)
skos:prefLabel	Shunji Takahashi (en) Shunji Takahashi (nl) Shunji Takahashi (tr) Shunji Takahashi (ast) 高橋俊二 (ja)
name	Shunji Takahashi (en) Shunji Takahashi (nl) Shunji Takahashi (tr) Shunji Takahashi (ast) 高橋俊二 (ja)
instance of	wds:Q88925476-63D53933-9D19-4752-A2A2-C4599376176C
instance of	Homo sapiens
Researchmap ID	wds:Q88925476-2f242a95-4d7d-4f50-47b8-b226ad6de111
Researchmap ID	read0194874
skos:altLabel	Takahashi Shunji (en)
occupation	wds:Q88925476-824CA4ED-4919-4D6F-BC0A-AC4768304966
employer	wds:Q88925476-ECD64939-CC11-4F31-87F7-CF35FA047F9A
CiNii Research ID	wds:Q88925476-DD708027-9B2F-43B3-9A77-2D968349C7CB
sex or gender	wds:Q88925476-d9fe4827-4132-54db-9cba-ccefd343ab09
country of citizenship	wds:Q88925476-ad65edae-4c8b-059c-ce5d-fe4f066177dd
family name	wds:Q88925476-15cacac1-4a51-44f9-6fef-f67f9cac663c
J-GLOBAL ID	wds:Q88925476-de759e83-4ecb-d546-6f17-3a69b1e8558b
CiNii Research ID	https://cir.nii.ac.jp/crid/1420001326214663296.rdf
occupation	researcher
employer	Japanese Foundation for Cancer Research
CiNii Research ID	1420001326214663296
sex or gender	male
country of citizenship	Japan
family name	Takahashi
J-GLOBAL ID	200901002513092947
ORCID iD	wds:Q88925476-5FE47D49-EC79-441D-8F58-07CF88AF9461
ORCID iD	https://orcid.org/0000-0002-5031-1953
ORCID iD	0000-0002-5031-1953
e-Rad researcher number	wds:Q88925476-e7bcc61b-4219-8827-3d89-d96c8dee5d17
e-Rad researcher number	90221358
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q88925476
is author of	Gene therapy for breast cancer. --Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study Nucleostemin expression in invasive breast cancer Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma. Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Max Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). Increased incidence of interstitial pneumonia by CHOP combined with rituximab Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer Lenvatinib for Anaplastic Thyroid Cancer. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan Flare-up of dermatomyositis along with recurrence of breast cancer Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer Gene therapy for breast cancer Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer Pancreatic islet cell carcinoma with multiple hepatic metastases successfully treated with a streptozocin/5-FU regimen--a case report Gene therapy for breast cancer Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin Retroviral integration site analysis and the fate of transduced clones in an MDR1 gene therapy protocol targeting metastatic breast cancer. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software